Tim Andrews, 67, is still alive and is back on the waiting list for a human donor. However, the success of his highly experimental procedure means more patients are scheduled to get genetically modified animal organs.
A new study published in JAMA, which looked at fee-for-service Medicare records from 2013–2023, found that overall participation has trended upward. However, the details paint a complicated picture.
Research that followed patients for more than 13 years suggests increases in ECG PR interval, P‐wave duration and PTFV1 are associated with increased AFib risk in this cohort.
Tim Andrews, 67, is still alive and is back on the waiting list for a human donor. However, the success of his highly experimental procedure means more patients are scheduled to get genetically modified animal organs.
A new study published in JAMA, which looked at fee-for-service Medicare records from 2013–2023, found that overall participation has trended upward. However, the details paint a complicated picture.
Research that followed patients for more than 13 years suggests increases in ECG PR interval, P‐wave duration and PTFV1 are associated with increased AFib risk in this cohort.
In some cases, researchers noted, CABG may be a better treatment option. The group emphasized that alternative therapies are still needed to improve patient care.
No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first?
